{"filings":[{"id":1508521,"accession_number":"0001829126-26-007394","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-07-08T12:00:28+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Zeo ScientifiX Q1 FY2026 revenue up 124.6% to $2.58M; net loss narrows to ~$1.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue for quarter ended Apr 30, 2026: $2.58M vs $1.15M a year ago, +124.6%.","Six-month revenue: $4.03M vs $2.24M, +79.9%, driven by allogenic biologic products.","Gross margins maintained at ~80% for both six-month periods.","Net loss for six months reduced to ~$1.0M from ~$2.6M in prior-year period.","CEO cites growing physician adoption and commercial momentum in Florida."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1369958,"accession_number":"0001829126-26-007111","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-07-01T11:30:22+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO ScientifiX to host educational webinar on regenerative medicine laws in Southeast","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Webinar titled 'One Year Later, Three States Stronger: The Southeast Regen Revolution' on July 22, 2026 at 6:45 p.m. ET.","Panel includes Dr. Sean Vega-Stanton, Dr. Michael Bellio, Dr. George Shapiro, and regulatory counsel Edgar Asebey.","Topics: lessons from Florida's first year of stem cell law, and implications of new laws in Tennessee and Georgia.","Event is for healthcare professionals; registration link provided in press release."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1066116,"accession_number":"0001829126-26-006515","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-06-16T11:45:30+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO donates products for pediatric burn reconstruction mission in Peru","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Dr. Constantino Mendieta used ZEO-donated products to treat ~38 child burn patients in Cusco, Peru.","10-day mission evaluated ~80 children; ~40 reconstructive surgeries performed at Regional Hospital of Cusco.","Mission supported by Aniquem, Fundación Aromas, and international medical volunteers.","Donation reflects ZEO's commitment to physician-led care and regenerative medicine education."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1027919,"accession_number":"0001829126-26-006446","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-06-12T20:21:49+00:00","items":["5.02"],"status":"ready","headline":"Zeo ScientifiX grants 625k options each to CEO, CMO, and major stockholder at $1.67; plus 80k to director","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Fully vested options for 625,000 shares each to Greyt Ventures (consultant/stockholder), CEO Ian Bothwell, and CMO George Shapiro; exercise price $1.67, 10-year term.","Performance-based incentive options for 625,000 shares each to same parties; vest upon milestone achievement, cashless exercise, $1.67 strike, 10-year term.","Non-executive director Chuck Bretz receives 80,000 fully vested options with $1.67 exercise price and 5-year term.","Incentive Options are antidilutive against any future transaction issuing 10% or more of fully diluted common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":927438,"accession_number":"0001829126-26-006218","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-06-09T11:05:36+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO ScientifiX expands Medical Advisory Board with nine new physicians in regenerative medicine","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New advisors include Andrea Asseff-Llanes (dental), Elizabeth Parrish (longevity), Faryal Farooqi (metabolic), Michael Swartzon (orthopedic sports medicine), and five others.","Board now spans orthopedics, oncology, longevity, pain management, plastic surgery, and advanced biologic therapies.","Advisory board will guide clinical protocols, physician education, and support XPRIZE Healthspan and A4M conferences.","Company emphasizes scientific rigor over marketing; board is not an endorsement vehicle.","Regenerative medicine legislation advancing in states like Georgia, Tennessee following Florida's lead."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":677558,"accession_number":"0001829126-26-005695","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-05-27T11:35:28+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZeoScientifiX launches Physician-Led Patient Masterclass; trained 600+ physicians in past year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Program formalizes patient education model that emerged from a physician-hosted event in Vero Beach, Florida.","Over 600 physicians trained in regenerative therapies across the Southeast in the past year.","Targets pain management, wound care, and orthopedics as permitted under Florida law.","Director of Growth Strategy cites strong patient demand and need for physician-led education on product quality.","General Manager states program scales clinical excellence and practice growth."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":25961,"accession_number":"0001829126-26-004982","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-05-12T14:09:21+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO ScientifiX monthly sales top $1M in April 2026 for first time","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Unaudited single-month sales surpassed $1.0 million in April 2026, a company first.","Milestone driven by new dedicated internal sales force and physician education masterclass programs.","Management calls it an inflection point; expects physician count, revenue per account, and total revenue to grow.","Company is actively recruiting additional full-time sales professionals to expand geographic reach and clinic penetration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93615,"accession_number":"0001829126-26-003684","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zeo ScientifiX surpasses 500 physicians trained in regenerative medicine Masterclass series","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Trained over 500 clinicians through monthly Masterclass series at Nova Southeastern University.","Masterclasses average 70+ attendees per month; next class April 24 at Nova Southeastern.","Program features faculty including healthcare attorney, Ph.D. researchers, and CMO Dr. Shapiro.","ZEO emphasizes 'education beats promotion' philosophy to navigate regulatory landscape."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93614,"accession_number":"0001829126-26-003301","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO signs MOU to be exclusive biologics supplier for Regen Therapy's 3,000-clinic network","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["MOU positions ZEO as core supplier of advanced biologic therapeutics for Regen Therapy's regenerative platform.","Regen Therapy's network includes over 3,000 clinics and 24,000 practitioners across the U.S.","Regen also partnered with Stealth Health for white-label telemedicine and longevity services.","No financial terms or binding agreement disclosed; MOU is non-definitive.","ZEO's expertise in extracellular vesicle and perinatal-derived therapeutics to support next-gen products."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93613,"accession_number":"0001829126-26-003240","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-04-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO ScientifiX selected as qualified team for XPRIZE Healthspan $101M competition semi-finals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Advancing to semi-finals of XPRIZE Healthspan; aims to develop therapeutics restoring muscle, cognitive, and immune function by 10-20 years in persons aged 65-80.","Assembled multidisciplinary team: Dr. Shapiro (CMO), Elizabeth Parrish (BioViva), Dr. Andrews (telomere biology), Dr. Kennedy (Buck Institute), and others.","Focus on extracellular vesicle (exosome) therapeutics and next-generation delivery systems targeting aging and inflammation biology.","Company operates labs at Nova Southeastern University; recently appointed as A4M regenerative medicine educational partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105392,"accession_number":"0001829126-26-002881","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO named official regenerative medicine educational partner for A4M; Masterclass Apr 9","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Role as official educational partner for regenerative medicine with A4M at Longevity SpringFest 2026.","Will lead full-day Masterclass on Apr 9, 2026 in West Palm Beach for physicians.","Access to A4M network of 26,000 physicians and practitioners from 120 nations.","Longevity therapy market estimated at $29.9 billion (The Business Research Company, 2026).","Partnership places ZEO alongside NASDAQ-listed Niagen Bioscience (NAGE) and InBody."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105391,"accession_number":"0001829126-26-002789","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-03-27T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zeo ScientifiX terminates Chief Science Officer Dr. John D. Kisiday","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Zeo ScientifiX terminated Dr. John D. Kisiday as Chief Science Officer, effective March 23, 2026.","No successor has been named, and the reason for termination was not disclosed.","The filing does not indicate any changes to the board or other executive officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105390,"accession_number":"0001829126-26-000610","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Zeo ScientifiX appoints Dr. John Kisiday as CSO with salary $175K and 50K stock grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kisiday, 55, has 30 years experience in tissue-engineering and regenerative medicine; started Jan 23, 2026.","Base salary of $175,000; eligible for performance bonus and new-opportunity royalty compensation.","Stock grant of 50,000 shares under 2021 Incentive Plan; 20K vest at 1yr anniversary, 30K at 2yr anniversary.","Severance: after 90 days, if terminated without cause or resigns for good reason, gets 1/4 month salary per 3 months completed.","Relocation reimbursement up to $10,000; initially remote from Colorado but expected to relocate to Florida headquarters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105389,"accession_number":"0001829126-26-000431","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zeo ScientifiX awards 350k restricted shares to CEO/CFO and CMO","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Each officer (Ian Bothwell, CEO/CFO; Dr. George Shapiro, CMO) granted 175,000 restricted shares.","Shares vest 50% at 8 months and 50% at one year from Jan 14, 2026 award date.","Grants made under 2021 Incentive Stock Plan; Bothwell and Shapiro are also board members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105388,"accession_number":"0001829126-26-000073","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zeo partners to commercialize Cytora's oral mucosal stem cell therapy under Florida law","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Zeo gets exclusive U.S. commercial rights to Cytora's allogeneic oral mucosal stem cell therapy (hOMSC200).","Initial commercialization under Florida SB 1768 for diabetic foot ulcers; estimated 125,000 new patients annually in Florida alone.","Phase 1/2a trial showed favorable safety and statistically significant complete wound closure in 27-month average-open ulcers.","Made Scientific handles GMP manufacturing at Princeton, NJ; Zeo provides market access, distribution, and clinical site management.","Partnership also plans U.S. FDA Phase 2b trial aiming for approved license."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105387,"accession_number":"0001829126-26-000029","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2026-01-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Ian Bothwell appointed full-time CEO of Zeo ScientifiX, retains CFO role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board appointed Ian T. Bothwell as full-time CEO effective December 24, 2025.","Mr. Bothwell had been serving as Interim CEO and CFO prior to the appointment.","He will continue to serve as Chief Financial Officer alongside the CEO role.","No officer resignations or departures were reported in connection with the change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121676,"accession_number":"0001829126-25-009662","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zeo ScientifiX terminates Chief Sales Officer Ron Borsheim effective Nov 30, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Ron Borsheim terminated as Chief Sales Officer – Aesthetics, effective November 30, 2025.","No successor or interim replacement named in the filing.","Reason for termination not disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121675,"accession_number":"0001829126-25-008357","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO ScientifiX positioned for Florida stem cell market growth after SB 1768 enactment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Florida SB 1768, effective July 1, 2025, allows physicians to administer non-FDA-approved stem cell therapies for orthopedic, wound care, and pain under cGMP.","ZEO expects revenue growth from increased physician demand, patient awareness, and medical tourism to Florida.","Company launched IRB-approved clinical study (PPX™) for musculoskeletal joint pathologies, targeting up to 350 patients; 5 clinics enrolled, 7 patients to date.","ZEO evaluating lab expansion at Nova Southeastern University for additional clean rooms and research space.","New law enables collection of real-world safety/outcome data, potentially lowering risks for future FDA submissions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138355,"accession_number":"0001829126-25-005526","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"Zeo ScientifiX raises $1M via private placement of 250k shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 250,000 common shares to one accredited investor for $1,000,000 at $4.00 per share.","Purchase price payable in 10 equal monthly installments from Aug 2025 to May 2026.","Exemption from registration claimed under Section 4(a)(2) of Securities Act."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138354,"accession_number":"0001829126-25-005232","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-07-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Dr. Peter Everts resigns as Chief Scientific & Technology Officer, effective Aug 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Peter A. M. Everts, Ph.D. resigned as Chief Scientific and Technology Officer.","Resignation effective August 1, 2025; no reason provided in filing.","No successor named at the time of the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138353,"accession_number":"0001829126-25-004961","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO ScientifiX launches expansion initiative following Florida's new stem cell law","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Florida's SB-1768, effective July 1, 2025, authorizes non-FDA-approved stem cell therapies for defined conditions.","ZEO launched a redesigned website (www.zeoscientifix.com) and partnered with Plus4 PR and Small Circle for brand growth.","CEO Ian Bothwell expects additional states to follow, positioning ZEO to lead with its cGMP-compliant biologics platform.","ZEO aims to set the industry standard via ethically sourced biologics, physician education, and compliant product inventory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155803,"accession_number":"0001829126-25-004668","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO launches physician masterclass ahead of Florida's SB-1768 stem cell therapy law","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Florida's SB-1768, effective July 1, 2025, permits MDs and DOs to offer non-FDA-approved stem cell therapies under strict compliance.","ZEO's Masterclass on June 27, 2025, at NOVA Southeastern University educates physicians on SB-1768 compliance and clinical integration.","Company positions itself as trusted supplier of compliant stem cell products via its FDA-registered facility.","No financial guidance, revenue impact, or clinical trial results included in the announcement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155802,"accession_number":"0001829126-25-003570","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["3.02","5.02"],"status":"ready","headline":"Zeo ScientifiX issues shares/warrants to consultant; grants options to execs and directors","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 100,000 shares and warrants for 500,000 shares to non-affiliated consultant under Section 4(a)(2) exemption.","Warrants vest in five equal tranches at exercise prices from $3.50-$10.00 per share; exercisable for 90 days after vesting.","Awarded 55,000 options each to CEO/CFO Ian Bothwell and CMO George Shapiro, fully vested at $2.86/share, 5-year term.","Awarded two grants of 5,000 options each to directors Bretz, Glauser, Stearn, and Singh: one fully vested, one with 2,000 immediate and 3,000 on Sep 23, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155801,"accession_number":"0001829126-25-002326","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Appoints Ron Borsheim as Chief Sales Officer - Aesthetics effective April 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Base salary of $225,000 per year; option to purchase 40,000 shares at $2.50/share.","Option vests 50% on first anniversary, 50% on second anniversary; five-year term.","Borsheim has 30+ years experience in aesthetic and regenerative medicine sales, previously at Benev Company, Sofwave Medical, BTL Industries.","Severance: 1/4 month salary per 3 months completed after 90 days if terminated without cause or for good reason.","Position reports to CEO; remote work from Jacksonville Beach, FL with travel to headquarters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174273,"accession_number":"0001829126-25-001049","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO ScientifiX appoints Dr. Peter A.M. Everts as Chief Scientific and Technology Officer","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Everts brings 35+ years of experience in orthobiology, spine, wound care, and regenerative medicine.","Previously CSO at EmCyte Corp and co-founder of Da Vinci Clinic, Netherlands; holds Ph.D. from University of Utrecht.","ZEO is a clinical-stage biopharmaceutical company focused on biological therapeutics for degenerative diseases.","Interim CEO Ian Bothwell says appointment underscores commitment to accelerating innovation and expanding regenerative therapies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174272,"accession_number":"0001829126-25-000863","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zeo ScientifiX update: Phase I Zofin trial complete, PPX revenue up $474K, partnerships expanded","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Completed Phase I safety trials for flagship Zofin; plans to amend INDs for Phase II targeting Osteoarthrosis and COPD.","PPX autologous product revenue increased by approximately $474,000 in FY2024 compared to prior fiscal year.","Issued patents for amniotic fluid processing techniques and PPX blood-derived exosome pain treatment method in past year.","Strategic partnership with Physicians Group LLC, operating 75 clinics and 750 clinicians, for collaborative research and clinical trials.","Launched ZEO HAIR GROW topical product with Exotropin; aims at hair loss market affecting 35M men and 31M women in US."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":174271,"accession_number":"0001829126-25-000818","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2025-02-10T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Zeo ScientifiX enters joint development MOU with BioXtek, appoints Dr. Peter Everts as CSO","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Binding MOU with BioXtek for joint development, manufacturing, marketing, and funding arrangement.","ZEO to relocate to BioXtek's 11,000 sq ft Pompano Beach facility by May 31, 2025.","Parties to form 50/50 SPE to pursue FDA BLA approval for membrane products.","Dr. Peter Everts appointed CSO; salary $220K first year, option for 25,000 shares at $3.05.","Severance: 1/4 month salary per 3 months after 90-day initial period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191218,"accession_number":"0001829126-24-008411","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-12-19T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Zeo ScientifiX amends Series C Preferred redemption terms to allow assignment with board consent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment permits assignment of Series C Preferred with prior board consent without triggering redemption.","Series C Preferred gives Skycrest Holdings and Greyt Ventures 25.5% voting power each (51% total).","Common stock ownership threshold for Skycrest/Greyt that triggers redemption provision has been adjusted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191214,"accession_number":"0001829126-24-007763","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K/A","filed_at":"2024-11-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zeo ScientiFix files 8-K/A to correct graphical error in ZEO HAIR GROW presentation slide","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Original Nov 15 8-K furnished PowerPoint on ZEO HAIR GROW product; amendment corrects graphical error in one slide.","Presentation by Exotropin co-founder Robin Smith at MAP meeting in Scottsdale, Arizona on Nov 15, 2024.","ZEO holds minority equity interest in Exotropin and collaborated on ZEO HAIR GROW product.","Corrected slide is furnished as Exhibit 99.1; no other changes to original filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191217,"accession_number":"0001829126-24-007559","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-11-15T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Zeo ScientifiX launches ZEO HAIR GROW exosome-based hair growth system at MAP conference","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Product introduced at Medical Aesthetics Professionals meeting in Scottsdale, AZ on Nov 15, 2024.","ZEO HAIR GROW combines three exosome sources (amniotic fluid, adipose-derived, aloe vera) plus growth factor booster.","System includes in-office induction procedure (GROWX+GROW BOOST) and at-home maintenance spray (EXO FOLLICLE FUEL).","Zeo holds minority equity interest in Exotropin; presentation by co-founder Dr. Robin L. Smith.","Company cites hair loss market: $3.5B spent on treatments, 66M Americans experiencing hair loss."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191216,"accession_number":"0001829126-24-007451","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO ScientifiX and Exotropin launch ZEO HAIR GROW hair growth system at MAP meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ZEO HAIR GROW Powered By Exotropin, a multipart hair growth system, to be introduced at MAP meeting Nov 14-16, 2024 in Scottsdale.","Product combines extracellular vesicles from amniotic fluid, adipose stromal cells, aloe vera to address hair loss.","System includes in-office components (ZEO GROW X, ZEO GROW BOOST) and at-home EXO FOLLICLE FUEL.","ZEO holds minority equity interest in Exotropin; Dr. Robin Smith will present at the conference.","Approximately 35M men and 31M women in US affected by hair loss, per ISHR."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191215,"accession_number":"0001829126-24-006793","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ZEO ScientifiX launches monthly regenerative medicine educational series for physicians","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["In-person events titled 'The Future of Biologic Medicine' focus on extracellular vesicles and autologous biologics.","First event held early September 2024; second on October 4; next forum scheduled November 8, 2024 in Davie, FL.","Events include expert-led discussions, lab tour at Nova Southeastern University, and regulatory overview.","Company completed Phase 1 trials for flagship product Zofin and is seeking Phase 2 trials for multiple indications.","Regenerative medicine market projected to reach ~$175B by 2032, 22.8% annual growth rate."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207681,"accession_number":"0001829126-24-006533","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Zeo ScientifiX partners with Physicians Group for Phase 2 clinical trials","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Physicians Group operates 75 clinics and 750+ clinicians, treating 1,500-2,000 patients monthly.","Collaboration targets Phase 2 trials of Zofin™ for several indications and other pipeline products.","Zeo completed Phase 1 for Zofin; aims for FDA approval for various diseases and chronic conditions.","Regenerative medicine market projected to reach ~$175B by 2032 with 22.8% CAGR per Precedence Research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207680,"accession_number":"0001829126-24-006382","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-09-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Zeo ScientifiX completes Phase 1 trials for Zofin; seeks Phase 2 trials","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Completed Phase 1 clinical trials for flagship product Zofin; actively seeking to commence Phase 2 trials for multiple indications.","Partnered with Exotropin to develop topical aesthetic and anti-aging products using exosome technology; holds minority stake.","Changed name from Organicell Regenerative Medicine to Zeo ScientifiX in February 2024 to reflect scientific focus.","Regenerative medicine market projected to grow to $175B by 2032 at 22.8% CAGR, per Precedence Research."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207679,"accession_number":"0001829126-24-005286","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["3.02","5.02"],"status":"ready","headline":"Zeo ScientifiX grants 700K warrants to controlling stockholders and 550K options to insiders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrants for 350,000 shares each granted to Skycrest Holdings and Greyt Ventures; exercise price $2.35.","Stock options totaling 550,000 shares granted to CEO/CFO Bothwell, CMO Shapiro, and directors Glauser, Stearn, and Bretz.","Both warrants and options vest monthly over 18 months and expire 10 years from grant date.","Potential total dilution of up to 1.25 million shares if all exercised; issued under Section 4(a)(2) exemption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207678,"accession_number":"0001829126-24-004757","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-07-12T23:59:59+00:00","items":["3.02","8.01"],"status":"ready","headline":"Zeo ScientifiX completes $500,000 private placement of 250,000 shares and warrants to accredited investor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private financing of $500,000 with a single accredited investor on July 8, 2024.","Issued 250,000 shares of common stock and warrants to purchase up to 83,333 additional shares.","Warrants have an exercise price of $2.00 per share and a ten-year term, exercisable on a cashless basis.","Granted piggy-back registration rights for the shares and warrant shares; also entered a supply agreement and a non-binding term sheet for clinical trial subsidiary investment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225150,"accession_number":"0001829126-24-003927","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zeo ScientifiX loses CEO and CSO; CFO Bothwell named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Dr. Harry Leider and CSO Dr. Howard Golub employment not renewed; both left May 31, 2024.","Leider also removed as director; may seek severance but company believes not entitled.","CFO Ian T. Bothwell appointed interim CEO effective June 1, 2024; board searching for permanent CEO and CSO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225149,"accession_number":"0001829126-24-002156","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Zeo ScientifiX awards stock grants to directors, boosts CFO salary to $250k","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stock grants of 125,000 shares to director Jerry Glauser and 62,500 to Leathem Stearn, fully vested on grant date.","Stock options for 5,000 shares each at $2.00 to directors Bretz, Glauser, Stearn, Singh; half vest immediately, half on 9/23/24.","CFO Ian T. Bothwell's base salary increased to $250,000, retroactive to January 1, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244373,"accession_number":"0001829126-24-001316","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Zeo ScientifiX (f/k/a Organicell) changes name and ticker to ZEOX effective March 5, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FINRA approved corporate name change from Organicell Regenerative Medicine to Zeo ScientifiX and symbol from OCEL to ZEOX, effective at market open March 5, 2024.","CUSIP number for common stock remains unchanged.","CEO Harry Leider highlighted Phase 1 completion, Phase 2 plans, and recent additions to the executive team."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244372,"accession_number":"0001829126-24-001107","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Zeo ScientifiX (fka Organicell) name change effective Feb 20; symbol change pending FINRA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company changed name from Organicell Regenerative Medicine, Inc. to Zeo ScientifiX, Inc. effective February 20, 2024.","Amendment filed with Nevada Secretary of State; FINRA review of new trading symbol not yet completed.","No financial or operational impact disclosed; name change is the only material item in this 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261802,"accession_number":"0001829126-23-007994","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-12-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Organicell Regenerative Medicine to change name to Zeo ScientifiX, Inc.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board and stockholders approved name change on December 8, 2023.","New name Zeo ScientifiX, Inc. to reflect focus on advanced biological therapeutics.","Effectiveness subject to SEC and FINRA regulatory compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261801,"accession_number":"0001829126-23-007678","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-11-27T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Organicell announces 1-for-200 reverse stock split effective Nov 27, reduces outstanding shares from 1.22B to ~6.12M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1:200 ratio effective close of business Nov 27, 2023; trading on post-split basis begins Nov 28 under ticker OCELD for 20 days.","Outstanding shares reduced from approximately 1,223,935,500 to about 6,119,678.","CEO Harry Leider states reverse split positions company for potential uplisting and improved marketability.","No fractional shares; one whole share issued for any fractional interest resulting from split.","Authorized shares unchanged; additional shares available for future capital raising but no specific plans."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261800,"accession_number":"0001829126-23-007435","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Organicell settles with former directors; recovers 232.8M shares","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Settlement with Albert Mitrani and Dr. Maria Ines Mitrani resolves Florida state action claims.","Albert Mitrani returned 136,432,152 shares; Maria Ines Mitrani returned 96,366,240 shares.","Mutual releases exchanged; no other financial terms disclosed.","Settlement effective November 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278984,"accession_number":"0001829126-23-005249","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-08-09T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"Organicell sells Basalt, CO laboratory for $1.25M plus lease assumption","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold Basalt, Colorado laboratory facility to non-affiliated third party for $1,250,000.","Purchaser assumed all remaining financial and other obligations under leases for premises and equipment.","Entered into non-exclusive distribution and commission agreements with purchaser.","Transaction effective August 7, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278983,"accession_number":"0001829126-23-004890","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organicell reports no safety events in Phase 1/2a studies of Zofin; plans Phase 2 in 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["No therapy-related safety events or significant adverse events across three Phase 1/2a studies with over 20 Zofin-treated patients.","Studies include knee osteoarthritis, moderate-to-severe COVID-19, and long-haul COVID-19 (expected completion October 2023).","Company plans to initiate larger Phase 2 studies for multiple chronic conditions in 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278982,"accession_number":"0001829126-23-004629","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-07-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Maria Ines Mitrani resigns from Organicell board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Maria Ines Mitrani resigned as a director effective July 11, 2023.","No reason for resignation disclosed in the 8-K filing.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297307,"accession_number":"0001829126-23-004464","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-06-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organicell appoints Howard Golub as EVP/CSO; 30+ years in clinical therapeutics","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Howard L. Golub, MD, PhD appointed EVP and Chief Science Officer effective June 29, 2023.","Dr. Golub brings over 30 years of clinical research experience, including VP R&D at Walgreens Boots Alliance and founding CareStat LLC.","He will lead Organicell's R&D for innovative regenerative biologic therapies.","CEO Harry Leider stated the appointment strengthens the company's research leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297306,"accession_number":"0001829126-23-004312","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-06-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Organicell appoints Harry Leider, MD, MBA as CEO effective June 21, 2023","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Leider most recently served as CMO/EVP at Gelesis, gaining FDA approval for Plenity and leading the company through a NYSE IPO.","He previously was CMO/Group VP at Walgreens Boots Alliance, leading clinical programs and health analytics across the Fortune 50.","As CEO, he will lead Organicell, a clinical-stage biopharma developing regenerative therapies from perinatal sources for chronic diseases.","Dr. Leider has over 25 years of healthcare executive experience, including roles at Ameritox, and academic appointments at Johns Hopkins and Harvard."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297305,"accession_number":"0001829126-23-004050","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-06-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Organicell sues former CEO Albert Mitrani and director Dr. Maria Ines Mitrani for breach of contract and fiduciary duty","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Complaint filed June 7, 2023 in Broward County, Florida, alleging breach of contract, fiduciary duty, tortious interference.","Claims non-solicitation/non-competition violations, misappropriation of proprietary materials and information.","Also alleges self-dealing by the Mitranis as officers, directors, and minority equity holders, causing irreparable harm.","Seeks injunctive relief plus compensatory and punitive damages."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297304,"accession_number":"0001829126-23-003953","cik":1557376,"company_name":"Zeo ScientifiX, Inc.","ticker":"ZEOX","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Organicell appoints Harry Leider as CEO and Howard Golub as CSO; Chairman Modi resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Bhupendra Kumar Modi stepped down as Chairman and director on June 4, 2023.","Harry Leider, M.D., M.B.A., appointed CEO and board member; base salary $325k, option for 57M shares at $0.012.","Howard Golub, M.D., appointed EVP and Chief Science Officer; base salary $150k, part-time, option for 50M shares at $0.012.","Ian Bothwell continues as CFO, having served as interim CEO since Nov 2022.","Leider's option vests quarterly over 3 years; Golub's over 1 year; both have severance provisions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":13610000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-06-06T23:59:59+00:00|297304"}